Skip to content
The African Exponent DATA
Resources

Review pending. Every figure has been located on its cited source page in an AI-assisted source verification (matched to the document's text) (9 October 2026). Independent review has not yet been carried out, and these pages are not indexed.AI-assisted source check done; independent review pending; not indexed. About the review

Fidson Healthcare

FIDSON · Nigerian Exchange · Company statements

On this page
Company details
Legal name
Fidson Healthcare Plc
Listing
FIDSON on the Nigerian Exchange, active · ISIN NGFIDSON0006 (observed 2026-10-08)
Sector
Not classified (our classification from the stated principal activity)
Financial year ends
31 December

Overview

Year ended 31 December 2025 · annual report, signed / final · source

  • Revenue

    NGN 119 billion

    119,061,254 NGN thousands · p27

    +41.4% vs 2024

  • Operating profit / (loss)

    NGN 21.9 billion

    21,948,612 NGN thousands · p27

    +67.1% vs 2024

  • Profit / (loss) for the year

    NGN 9.88 billion

    9,883,576 NGN thousands · p27

    +124.7% vs 2024

  • Total assets

    NGN 80.3 billion

    80,286,939 NGN thousands · p28

    +9.2% vs 2024

  • Total equity

    NGN 30.2 billion

    30,196,827 NGN thousands · p28

    +35.1% vs 2024

  • Cash from operations

    NGN 16.8 billion

    16,821,008 NGN thousands · p30

    Change not shown.

Large amounts are rounded for reading (NGN million / billion / trillion); exact figures as printed are under each amount and in the tables. No currency conversion.

Not shown: the prior-year figure is zero or negative.

Financial statements

Exact figures as printed. Each column comes from one filing; labels are as printed in the newest filing. Amounts in NGN thousands unless the row says otherwise; brackets are negative.

† from a supplementary filing for the same year · ‡ signed audited statements preferred over a disputed figure · “–” is a printed dash, explained below the table

Column sources

  • FY2025 — annual report, signed / final; reported for the year · source
  • FY2024 — annual report, signed / final; comparative in the FY2025 filing · source

Income statement

Income statement, NGN thousands. Columns: FY2025 — annual report (signed / final), as reported for the year; FY2024 — annual report (signed / final), comparative reported in the annual report for 2025.
Line (as printed) FY2025Annual reportreported for the yearFY2024Annual reportcomparative in FY2025 filing
Revenue 119,061,254 84,189,000
Cost of Sales (69,835,197) (49,084,616)
Gross profit 49,226,057 35,104,384
Other gains and losses 887,547 611,871
Administrative expenses (12,396,055) (8,712,125)
Impairment of receivables (133,069) (301,440)
Net exchange loss (6,012,067) (5,448,891)
Selling and distribution expenses (9,623,801) (8,119,539)
Operating profit 21,948,612 13,134,260
Finance costs (7,130,319) (5,493,822)
Finance income 144,315 60,022
Profit before tax 14,962,608 7,700,460
Income tax * (5,079,032) (3,301,497)
Profit for the year * 9,883,576 4,398,964
Other comprehensive income, net of tax; 30,242 30,198
Total comprehensive income, net of tax * 9,913,818 4,429,162

Balance sheet

Balance sheet, NGN thousands. Columns: FY2025 — annual report (signed / final), as reported for the year; FY2024 — annual report (signed / final), comparative reported in the annual report for 2025.
Line (as printed) FY2025Annual reportreported for the yearFY2024Annual reportcomparative in FY2025 filing
Property, plant and equipment 30,937,846 25,125,748
Right of use of assets –1 –1
Intangible assets 238,235 65,471
Financial assets at FVTOCI 12,360 9,100
Financial assets at amortised cost 20,498 17,915
Other non-current financial asset2 215,936 198,106
Non-current assets (unlabelled subtotal) 31,424,875 25,416,340
Inventories 26,547,162 24,182,294
Financial assets at amortised cost –3 242,230
Trade and other receivables 11,068,227 6,208,214
Prepayments4 6,535,857 12,513,033
Cash and cash equivalents 4,710,818 4,931,368
Total current assets 48,862,064 48,077,140
Total assets 80,286,939 73,493,480
Share capital 1,200,000 1,147,498
Share premium 5,009,225 4,829,614
Retained earnings * 23,979,687 16,364,125
Financial asset reserve 7,915 4,655
Total equity 30,196,827 22,345,892
Interest bearing loans and borrowings 3,596,236 7,018,279
Retirement benefit obligation 160,139 251,090
Government grant5 207,267 590,618
Deferred tax liability * 4,676,505 3,836,609
Non-current liabilities (unlabelled subtotal) 8,640,147 11,696,596
Trade and other payables 6,630,781 10,370,733
Interest bearing loans and borrowings 10,407,067 8,979,029
Bank Overdraft 9,528 1,283,797
Other financial liabilities6 19,645,345 15,646,950
Government grant5 427,488 687,468
Income tax payable 4,250,709 2,349,129
Unclaimed dividend7 79,048 133,887
Current liabilities (unlabelled subtotal) 41,449,966 39,450,993
Total liabilities 50,090,112 51,147,589
Total equity and liabilities 80,286,939 73,493,480
  1. Printed “-”, read as nil: subtotal_arithmetic: bs.non_current_assets.
  2. Printed “-”, read as nil: subtotal_arithmetic: bs.current_assets.
Notes and alternative reported figures (5)
  1. “Other non-current financial asset” is an issuer-specific line, not mapped to a shared definition: Note 19.
  2. “Prepayments” is an issuer-specific line, not mapped to a shared definition: Note 22: current; printed apart from trade and other receivables.
  3. “Government grant” is an issuer-specific line, not mapped to a shared definition: Note 26: deferred government grant.
  4. “Other financial liabilities” is an issuer-specific line, not mapped to a shared definition: Current (note 28).
  5. “Unclaimed dividend” is an issuer-specific line, not mapped to a shared definition: Current (note 29(b)).

Cash flow

Cash flow, NGN thousands. Columns: FY2025 — annual report (signed / final), as reported for the year; FY2024 — annual report (signed / final), comparative reported in the annual report for 2025.
Line (as printed) FY2025Annual reportreported for the yearFY2024Annual reportcomparative in FY2025 filing
Cash generated from operations (unlabelled subtotal) 19,170,128 189,984
Income tax paid (2,349,120) (839,094)
Net cash flows generated / (used in) from operating activities 16,821,008 (649,110)
Purchase of property, plant & equipment (8,016,748) (3,693,094)
Additions to intangible assets (463,131) (175,489)
Interest received 119,028 44,617
Proceeds from sale of property, plant and equipment 96,155 2,970
Proceeds from sale of right of use asset1 –2 336
Net cash flows utilized by investing activities (8,264,696) (3,820,660)
Interest paid on borrowings (3,941,758) (1,796,209)
Interest paid on financial liabilities3 (2,464,168) (3,152,716)
Dividend paid (2,294,996) (1,376,998)
Received/(Refund) of unclaimed dividend4 (54,839) 33,142
Proceed from loans & borrowings 6,000,000 8,300,000
Proceed from other financial liabilities5 19,645,345 15,646,950
Loan repayment (Principal)- Other financial liabilities6 (15,646,950) (10,000,000)
Loan repayment (Principal) (8,709,925) (9,685,504)
Net cash flows used in financing activities (7,467,291) (2,031,334)
Net increase/ (decrease) in cash and cash equivalents 1,089,021 (6,501,104)
Effect of foreign exchange difference (35,302) 143,816
Cash and cash equivalents at beginning of year 3,647,571 10,004,859
Cash and cash equivalents, at end of the year 4,701,290 3,647,571
  1. Printed “-”, read as nil: subtotal_arithmetic: cf.cash_from_investing.
Notes and alternative reported figures (5)
  1. “Proceeds from sale of right of use asset” is an issuer-specific line, not mapped to a shared definition: Investing activities.
  2. “Interest paid on financial liabilities” is an issuer-specific line, not mapped to a shared definition: Financing activities (note 11).
  3. “Received/(Refund) of unclaimed dividend” is an issuer-specific line, not mapped to a shared definition: Financing activities (note 29(b)).
  4. “Proceed from other financial liabilities” is an issuer-specific line, not mapped to a shared definition: Financing activities (note 28).
  5. “Loan repayment (Principal)- Other financial liabilities” is an issuer-specific line, not mapped to a shared definition: Financing activities (note 28).

Per share and shares

Per share and shares. Columns: FY2025 — annual report (signed / final), as reported for the year; FY2024 — annual report (signed / final), comparative reported in the annual report for 2025.
Line (as printed) FY2025Annual reportreported for the yearFY2024Annual reportcomparative in FY2025 filing
Earnings / (loss) per share (per share)3 4.121 1.922
  1. Printed as 412 kobo; value converted to NGN at 100 kobo = 1 NGN.
  2. Printed as 192 kobo; value converted to NGN at 100 kobo = 1 NGN.
Notes and alternative reported figures (1)
  1. Earnings / (loss) per share: printed as “* Basic and diluted”.

Segments

Segment data not yet collected for this company in the pilot.

Dividends

Proposed or recommended, declared and paid are different events and are kept apart. A statement that no dividend was proposed does not mean none was paid.

Dividend events, the issuer's wording, and amounts as printed
Year endedEventWording as printedAmountUnitSource
31 Dec 2025 Dividends paid (cash flow statement) Dividend paid (2,294,996) NGN thousands Annual report, p30
31 Dec 2024 Dividends paid (cash flow statement) Dividend paid (1,376,998) NGN thousands Annual report, p30

Sources

Each filing used on this page, newest period first. Dates are the document's own; the date we retrieved a file is shown separately and is never a publication date.

  • Fidson Healthcare Plc Annual Report and Financial Statements for the year ended 31 December 2025

    Year ended 31 December 2025 · Annual report · signed / final

    Audit: Deloitte & Touche (Chartered Accountants), Lagos, unmodified opinion · signed

    Auditor's sign-off: Folorunso Hunga, FCA, for Deloitte & Touche

    Final status: Independent auditor's report to the shareholders of Fidson Healthcare Plc (scanned, PDF pp22-24; opinion p22) signed by hand for Deloitte & Touche (Folorunso Hunga, FCA, FRC/2013/PRO/ICAN/004/00000001709) with the ICAN seal, 'Lagos, Nigeria, 31 March 2026' (the day handwritten), PDF p24, page image. The statement of financial position was 'Signed on Behalf of the Board of Directors on 26th March 2026' with handwritten signatures of Abiola Adebayo (Managing Director/CEO) and Imokha Ayebae (Finance Director) (PDF p28, also p21, page image).

    Document date
    31 Mar 2026
    Auditor's report
    31 Mar 2026
    Board approval
    26 Mar 2026
    Retrieved by us
    8 Oct 2026 (not a publication date)
    Used for
    statement columns FY2025, FY2024
    Basis
    company statements · NGN thousands (printed “N '000”)
    • Cash and cash equivalents at the end of the year in the cash flow statement (4,701,290; 2024: 3,647,571, p30) are net of the bank overdraft (9,528; 2024: 1,283,797) printed under current liabilities (p28); balance-sheet cash is 4,710,818 (2024: 4,931,368).
    • The signed statement of financial position (folio 26) is printed twice: at PDF p21, before the scanned auditor's report, and at p28 in sequence; both pages carry the same text layer and figures. Transcribed from p28.
    • Note 44 (PDF p84): the 2024 comparatives are restated for an understatement of deferred tax (wrong calculation of the closing balance): tax expense 1,921,076 -> 3,301,496, profit 5,779,384 -> 4,398,964, retained earnings 17,744,545 -> 16,364,125, total equity 23,726,312 -> 22,345,892, deferred tax liabilities 2,456,188 -> 3,836,608, total non-current liabilities 10316175 -> 11,696,595, EPS 252 -> 192 kobo. The primary statements print 3,301,497 (tax), 3,836,609 (deferred tax) and 11,696,596 (non-current liabilities): 1 apart from the note. Kept as printed on the statements; the starred rows are marked restated.
    • Earnings per share is printed in kobo (412; 2024 restated: 192, basic and diluted, p27); stored in naira with the printed figure and unit kept.
    • No emphasis-of-matter or going-concern paragraph in the auditor's report (pp22-24, page images). The auditor separately reports a limited-assurance engagement on internal control over financial reporting with no exception (assurance report also dated 31 March 2026, PDF pp25-26).
    Technical details
    File
    87 pages, with a text layer
    SHA-256
    2ac3c80aa1b123eda12ef3ddf933f4decad68ebc6e337bfc3f06b49189ef86cf
    Entity as printed
    Fidson Healthcare Plc
    Exchange copy
    retrieved 2026-10-08T18:00:30Z

Data notes

No figure-level notes beyond those in the tables.

Review status: every figure has been located on its cited source page in an AI-assisted source verification (matched to the document's text) (9 October 2026). Independent review is pending for every figure; automated checks and the AI-assisted verification are not independent review.

Download

Figures shown on this page (CSV) — the same selected figures at their exact printed values, each with its source document, SHA-256, page, selection rule and reading. Independent review of these figures is pending.

· Company methodology and coverage